Table 3.

Univariate analyses of clinical and pathological variables in patients with stages I–III breast cancers

	N (%)	DFS			OS
		HR	95% CI	P-value	HR	95% CI	P-value
Age				0.0129			0.0191
<36 years	26 (6%)	1.00			1.00
36–50 years	204 (49%)	0.41	0.23–0.76		0.40	0.20–0.77
>50 years	186 (45%)	0.50	0.28–0.91		0.48	0.25–0.92
Tumor size				<0.0001			<0.0001
≤2 cm	167 (40%)	1.00			1.00
3–5 cm	216 (52%)	1.86	1.18–2.92		2.27	1.28–4.02
>5 cm	33 (8%)	5.43	3.02–9.79		7.99	4.04–15.84
Axillary lymph nodes				<0.0001			<0.0001
None	232 (56%)	1.00			1.00
1–3	96 (23%)	1.98	1.17–3.35		1.92	0.99–3.70
4–9	54 (13%)	3.81	2.22–6.53		4.67	2.49–8.75
≥10	34 (8%)	12.08	7.19–20.30		11.81	6.47–21.55
AJCC stage				<0.0001			<0.0001
I	114 (27%)	1.00			1.00
II	209 (50%)	3.23	1.53–6.84		4.10	1.45–11.62
III	93 (22%)	11.11	5.27–23.40		16.43	5.90–45.80
ER expression				0.0090			0.0001
Positive	261 (63%)	1.00			1.00
Negative	155 (37%)	1.65	1.13–2.42		2.35	1.50–3.69
PR expression				<0.0001			<0.0001
Positive	257 (62%)	1.00			1.00
Negative	159 (38%)	2.12	1.44–3.13		2.67	1.68–4.22
Histologic subtype				0.7717			0.8421
Ductal	391 (94%)	1.00			1.00
Lobular	8 (2%)	1.09	0.27–4.44		0.75	0.10–5.40
Mucinous	13 (3%)	1.03	0.33–3.23		0.87	0.21–3.55
Others	4 (1%)	NA	NA		NA	NA
Histologic grade				0.0072			0.0010
I	103 (25%)	1.00			1.00
II	164 (39%)	2.07	1.14–3.77		1.88	0.89–3.99
III	98 (24%)	2.88	1.55–5.36		3.75	1.78–7.88
Not available	51 (12%)	1.84	0.85–3.98		1.98	0.79–5.00
Neoadjuvant or adjuvant chemotherapy				0.0010			0.0013
Yes	262 (63%)	1.00			1.00
No	154 (37%)	0.49	0.31–0.75		0.43	0.25–0.73

HR: hazard ratio; CI: confidence interval; NA: not available